---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-021665"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:33:13.547167+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte reports Q1 net loss $95M, cash $1.9B; VAX-31/24 enrollment complete

## Summary
- Cash, equivalents and investments $1.9B at March 31, 2024, up from $1.24B at Dec 31, 2023, including $816.5M net from Feb offering.
- Net loss $95.0M vs $60.5M in Q1 2023; R&D expenses rose to $94.6M from $58.1M.
- VAX-31 adult Ph1/2 enrollment completed; topline safety/immunogenicity data expected Q3 2024.
- VAX-24 infant Ph2 enrollment completed; topline data from primary series expected by end Q1 2025.
- Plan to advance either VAX-24 or VAX-31 to adult Ph3 after VAX-31 data; if VAX-24, Ph3 start H2 2024.

## SEC filing metadata
- accession: 0001628280-24-021665
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000162828024021665/0001628280-24-021665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000162828024021665/pcvx-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-021665
- JSON: https://secwatch.observer/filing/0001628280-24-021665.json
- Plain text: https://secwatch.observer/filing/0001628280-24-021665.txt

## Key facts
- Earnings Releases
  Vaxcyte, Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000162828024021665/0001628280-24-021665-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.